Needle-free insulin injection improves blood sugar control and reduces pain in hospitalized type 2 diabetes patients

• Needle-free insulin injection achieved significantly better glycemic control than conventional insulin pens during short-term intensive therapy
• Glucose variability was reduced with needle-free injection, as shown by higher time in range and lower glycemic excursion amplitudes
• Needle-free devices caused substantially less injection pain and improved patient satisfaction without increasing hypoglycemia risk

This study enrolled hospitalized adults aged 18-70 with type 2 diabetes requiring intensive insulin therapy, including newly diagnosed patients with HbA1c ≥9% or FPG ≥11.1 mmol/L, or those with persistent poor control despite 3 months of oral medications. Average participants were in their early 40s, overweight, and had moderately high baseline glucose levels.

This was a very short study in a hospital setting with intensive monitoring that may not reflect real-world outpatient use. The open-label design means participants and staff knew which device was being used, which could affect subjective outcomes like pain and satisfaction ratings. Longer studies are needed to determine if these benefits persist over months or years and whether needle-free devices improve long-term adherence and outcomes. The study also didn't assess cost-effectiveness or device availability issues.

• Very short study duration (12 days) limits understanding of long-term effectiveness and sustainability
• Small sample size (63 participants) from single hospital reduces generalizability
• Conducted only in hospitalized patients, unclear if results apply to outpatient settings
• Open-label design may have influenced subjective outcomes like pain and satisfaction